Ensysce Biosciences, Inc.
ENSC
Positions held
Your positionsENSC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $8.91M | Enterprise value | $8.10M | Trailing P/E | — | Forward P/E | -9.16 |
| PEG | — | Price / book | -9.54 | Beta | 1.02 | Dividend yield | 0.00% |
| Revenue growth | -15.1% | Earnings growth | — | Gross margin | -1.8% | Operating margin | -2.2% |
| Profit margin | -2.8% | ROE | -13.0% | ROA | -1.9% | Debt / equity | — |
| Current ratio | 0.70 | Free cash flow | -$4.15M | Analyst recommendation | none | Mean target | $8.25 |
| 52w high | $2.75 | 52w low | $0.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$2.6M | -$3.6M | -$2.8M | -$3.7M | -$1.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$2.6M | -$3.6M | -$2.8M | -$3.7M | -$1.8M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$10.2M | -$8.0M | -$10.6M | -$24.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$10.2M | -$6.7M | -$10.7M | -$24.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-15 · Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
2026-09-02 · Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
2026-08-31 · Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
2026-08-20 · Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
2026-08-18 · Ensysce Biosciences Insider Bought Shares Worth $444,169, According to a Recent SEC Filing
2026-08-14 · ENSC Sets Itself Up Nicely for Critical Stage
2026-08-13 · Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-06 · Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing
2026-08-06 · BC-Most Active Stocks
2026-08-06 · Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Price (daily)
Full chart · RSI · MACD · patterns